🇺🇸 FDA
Patent

US 11155523

Biphenyl compound as CCR2/CCR5 receptor antagonist

granted A61PA61P29/00

Quick answer

US patent 11155523 (Biphenyl compound as CCR2/CCR5 receptor antagonist) held by Medshine Discovery Inc. expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P29/00